drugset / Trial / NCT01593592

Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients

NCT01593592

RandomizedParallel-groupTriple-blindTreatment

Summary

Addition of L. reuteri to the standard triple therapy improves H. Pylori treatment outcomes.

Timeline

Start
2012-06
Primary completion
2013-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Amoxicillin Other / unclassified 1000 mg
Background Clarithromycin Small molecule 500 mg
Background Omeprazole Other / unclassified 20 mg